Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant

NCT05271630 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

69

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

OTHER: Autologous Stem Cell Transplant
DRUG: Immunomodulatory Agent
DRUG: Proteasome Inhibitor

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]